ERBB2 and neoplasm: Although there are no FDA-approved tumor vaccines for GC treatment on the market, the field has a very promising future, and tumor vaccines including the MG-7-DC vaccine (NCT04567069), the OTSGC-A24 peptide vaccine (NCT03784040), and the peptide vaccine targeting HER2, IMU-131 (HER-Vaxx) (NCT02795988) are being investigated on GC.